ScholarIQanswers from OpenAlex
Head and Neck Cancer Studies
TopicLeading institutions, researchers & key papers
Head and Neck Cancer Studies is a topic indexed in ScholarIQ from OpenAlex.
What is known about Head and Neck Cancer Studies?
ScholarIQrecord summary
This cluster of papers focuses on the epidemiology, treatment, and prognosis of head and neck cancer, with a particular emphasis on human papillomavirus (HPV)-related oropharyngeal cancer. It covers topics such as the impact of HPV infection, the role of radiotherapy and chemotherapy, survival outcomes, and the molecular landscape of head and neck squamous cell carcinomas.
How many works does Head and Neck Cancer Studies have?
ScholarIQindexed works
Head and Neck Cancer Studies has 511 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Head and Neck Cancer Studies?
ScholarIQopenalex
The OpenAlex for Head and Neck Cancer Studies is on the source record.
What are the most-cited papers on Head and Neck Cancer Studies?
ScholarIQmost cited works
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
K. Kian Ang, Jonathan Harris, Richard Wheeler, Randal S. Weber, David I. Rosenthal, Phuc Félix Nguyen‐Tan, William H. Westra, Christine H. Chung, Richard C. Jordan, Charles Lu, Harold Kim, Rita Axelrod, C. Craig Silverman, Kevin P. Redmond, Maura L. Gillison
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J. Geese, Justin Kopit, James W. Shaw, Maura L. Gillison
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett Hughes, Ricard Mesı́a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey‐Long Hong, René González Mendoza, Ananya Roy, Yayan Zhang, Burak Gümüşçü, Jonathan D. Cheng, Fan Jin, Danny Rischin, Guillermo Lerzo, Marcelo Tatangelo, Mirta Varela, Juan José Zarbá, Michael Boyer, Hui Gan, Bo Gao, Brett Hughes, Girish Mallesara, Danny Rischin, Anne L. Taylor, Martin Burian, Thorsten Fuereder, Richard Greil, Carlos H. Barrios, Dalvaro Oliveira de Castro Junior, Gilberto de Castro, Fábio Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Vieira dos Santos, Ana-Paula Victorino, Neil Chua, Félix Couture, Richard Gregg, Aaron R. Hansen, John Hilton, Joy McCarthy, Denis Soulières, Rodrigo Ascuí, Pablo Gonzalez, Luis J. Villanueva-Rivera, Marco Torregroza, Ángela R. Zambrano, Petra Holečková, Zdeněk Král, Bohuslav Melichar, Prausova Jana, Milan Vošmik, Maria Andersen, Niels Gyldenkerne, Hannes Jürgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Amanda Psyrri, D.L.W. Kwong, Yousuf Al-Farhat, Tibor Csőszi, József Erfán, Geza Horvai, László Landherr, Éva Remenár, Ágnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nolè, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi
Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
Arlene A. Forastiere, Helmuth Goepfert, Moshe Maor, Thomas F. Pajak, Randal S. Weber, William H. Morrison, Bonnie S. Glisson, Andy Trotti, John A. Ridge, C. Chao, Glen Peters, Ding-Jen Lee, Andrea Leaf, John F. Ensley, Jay S. Cooper
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra, Myung‐Ju Ahn, Ainara Soria, Jean‐Pascal Machiels, Nicolas Mach, Ranee Mehra, Barbara Burtness, Pingye Zhang, Jonathan D. Cheng, Ramona F. Swaby, Kevin J. Harrington, Mirelis Acosta-Rivera, Douglas R. Adkins, Morteza Aghmesheh, Myung‐Ju Ahn, Mario Airoldi, Eduardas Aleknavičius, Yousuf Al-Farhat, Alain P. Algazi, Salah Almokadem, Anna Alyasova, Jessica R. Bauman, Marco Benasso, Alfonso Berrocal, Victoria Bray, Barbara Burtness, Francesco Caponigro, Ana Castro, Terrence P. Cescon, Kelvin Chan, Arvind Chaudhry, Bruno Chauffert, Ezra E.W. Cohen, Tibor Csőszi, Jan Paul de Boer, Jean‐Pierre Delord, Andreas Dietz, José Dinis, Charlotte Dupuis, Laurence Digue, József Erfán, Yolanda Escobar Alvarez, Mererid Evans, Mary J. Fidler, Martin Förster, Signe Friesland, Apar Kishor Ganti, Lionnel Geoffrois, Clíona Grant, Viktor Gruenwald, Kevin J. Harrington, Thomas K. Hoffmann, Geza Horvai, Arturas Inčiūra, Raymond Woo-Jun Jang, Petra Jankowska, Antonio Jimeno, Mano Joseph, Alejandro Juárez Ramiro, Bogusława Karaszewska, Andrzej Kawecki, Ulrich Keilholz, Ulrich Keller, Sung‐Bae Kim, Judit Kocsis, Nuria Kotecki, Mark Kozloff, J. Lambea, László Landherr, Yuri Lantsukhay, Sergey Lazarev, Lip Way Lee, Christophe Le Tourneau, Lisa Licitra, Igor Lifirenko, Nicolas Mach, Danko Martincic, О. В. Маторин, Margaret McGrath, Jean‐Pascal Machiels, Ranee Mehra, Krzysztof Misiukiewicz, John C. Morris, Ф. Ф. Муфазалов, Jiaxin Niu, Devraj Srinivasan, Pedro Pérez Segura, Daniel Rauch, Maria Leonor Ribeiro, Cristina P. Rodriguez, Frédéric Rolland, Antonio Russo, Ágnes Ruzsa, Frederico Sanches, Sangwon Shin, Mikhail Shtiveland
Where is Head and Neck Cancer Studies research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
The Lancet4,986
PubMed1,370
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Head and Neck Cancer Studies is open access?
ScholarIQopen access share
73%OPEN ACCESS